Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 101–200 of 647
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 49
“In recent decades, research on psychedelic treatments for mental disorders has gained new interest [1].”
BackgroundInfluentialA Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 47
“6 This revival of research in psychedelic compounds is spurred by unmet needs in regard to the treatment of mental illnesses.”
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., & Sergent, F. (2025) · Addiction · doi:10.1111/add.70152 · Cited by 43
Gard, D. E., Pleet, M. M., Bradley, E. R., Penn, A. D., Gallenstein, M. L., Riley, L. S., DellaCrosse, M., Garfinkle, E. M., Michalak, E. E., & Woolley, J. D. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100240 · Cited by 36
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019
Walsh, C. A., Livne, O., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100454 · Cited by 43
“…in treating depression (Berman et al., 2000; Carhart-Harris et al., 2016; Galvez et al., 2014; Griffiths et al., 2016), substance use disorders (Reiff et al., 2020), and post-traumatic stress disorder (Ivan Ezquerra-Romano, Lawn, Krupitsky, & Morgan, 2018; Reiff et al., 2020), notably in those…”
BackgroundAicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 38
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 40
Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022) · Cureus · doi:10.7759/cureus.21944 · Cited by 63
“When psychotic illness does occur, it is thought to be due to the expression of a predisposition rather than the drug creating the disorder [36].”
BackgroundStrauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2022) · Frontiers in Forests and Global Change · doi:10.3389/ffgc.2022.813998 · Cited by 33
“To date, human and animal studies have shown that psilocybin is non-addictive and has shortand long-term benefits in mood disorders, abuse disorders and chronic pain (Amsterdam et al., 2011; Carhart-Harris et al., 2016; Hanks and González-Maeso, 2016; Tyls et al., 2016; Hartman, 2018; Johnson et al., 2018; Dos Santos…”
BackgroundThe Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
Johnston, C. B., Mangini, M., Grob, C. S., & Anderson, B. T. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.08.007 · Cited by 40
“T he past decade has seen a groundswell of interest in the use of psychedelic medicines for conditions such as post-traumatic stress disorder (PTSD) and the distress associated with a serious medical illness.(1) The enthusiasm for these compounds is understandable, given the dramatic accounts of improvement reported i…”
BackgroundValidation of a new instrument for assessing attitudes on psychedelics in the general population
Žuljević, M. F., Buljan, I., Leskur, M., Kaliterna, M., Hren, D., & Duplančić, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-23056-5 · Cited by 44
McMillan, R. M., & Fernandez, A. V. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221139962 · Cited by 39
“During integration sessions, patients discuss their psychedelic experiences with therapists to interpret purported insights gained from the experience (Reiff et al., 2020).”
BackgroundPsychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“A growing body of research supports the administration of 5-HT2AR agonist classic psychedelics such as psilocybin and LSD as a potential treatment for various conditions, including anxiety, mood, and substance use disorders (Garcia-Romeu et al. 2016; Reiff et al. 2020).”
BackgroundGiving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
Cavanna, F., Pallavicini, C., Milano, V., Cuiule, J. I., Tella, R. D., González, P., & Tagliazucchi, E. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00172 · Cited by 35
“In recent years, the scientific and clinical interest in psychedelics has increased considerably as a consequence of a new wave of research demonstrating their potential in neuroscience, psychiatry, and as adjuncts for psychotherapy (Johnson & Griffiths, 2017; Kleber, 2016; Nichols & Hendricks, 2020; Nutt & Carhart-Ha…”
Barnett, B. S., Arakelian, M. H., Beebe, D. S., Ontko, J., Riegal, C., Siu, W. O., Weleff, J., & Pope, H. G. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0036 · Cited by 36
“5 Given accumulating data supporting the therapeutic potential of classic hallucinogens 6 and possibly increasing cultural acceptance of these drugs, as evidenced by rising non-medical use of them, 7,8 we conducted a repeat national survey of American psychiatrists’ opinions about classic…”
Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Lee, A., Rosenbaum, D., & Buchman, D. Z. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231225937 · Cited by 35
The Altered States Database: Psychometric data from a systematic literature review
Prugger, J., Derdiyok, E., Dinkelacker, J., Costines, C., & Schmidt, T. T. (2022) · Scientific Data · doi:10.1038/s41597-022-01822-4 · Cited by 36
“The second screening step resulted in the exclusion of 38 full texts that did not contain accessible data and were therefore Questionnaire Versions Scales/Factors Original publication Altered States of Consciousness Rating Scale APZ (1) Oceanic Boundlessness, (2) Dread of Ego Dissolution, (3) Visionary Restructuraliza…”
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
“Recently, psychedelic drugs including psilocybin and 3,4-methylenedioxy methamphetamine (MDMA) have been given the status of a breakthrough medicine by the FDA in the United States [71].”
BackgroundEmmerich, N., & Humphries, B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000099 · Cited by 37
The therapeutic potential of psychedelics: the European regulatory perspective
Butlen‐Ducuing, F., McCulloch, D. E.-W., Haberkamp, M., Mattila, T., Bałkowiec-Iskra, E., Aislaitner, G., Balabanov, P., Lundberg, J., Stenbæk, D. S., Elferink, A. J. A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00264-7 · Cited by 33
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
Cavarra, M., Mason, N. L., Kuypers, K. P. C., Bonnelle, V., Smith, W., Feilding, A., Kryskow, P., & Ramaekers, J. G. (2023) · European Journal of Pain · doi:10.1002/ejp.2171 · Cited by 37
“Research to test their analgesic effects began before the war on drugs era (Reiff et al., 2020) and evidence of their efficacy was gathered in neuropathic, ischemic or cancer-related pain https://www.zotero.org/google-docs/?KCQPdx (Grof et al., 1973; Kast & Collins, 1963), life-threatening…”
BackgroundDellaCrosse, M., Pleet, M., Morton, E., Ashtari, A., Sakai, K., Woolley, J., & Michalak, E. (2022) · PLOS ONE · doi:10.1371/journal.pone.0279073 · Cited by 28
“These findings led the Food and Drug Administration (FDA) to designate psilocybin as a “breakthrough therapy” for depression [29, 30].”
Sapienza, J., Bosia, M., Spangaro, M., Martini, F., Agostoni, G., Cuoco, F., Cocchi, F., & Cavallaro, R. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01721-5 · Cited by 30
“Clinical implications and future directions Nowadays, despite therapeutic implications have been widely described for major depressive disorder and other psychiatric diseases, it is hard to think that SP can help us in dealing with schizophrenia, as SP induce psychotic symptoms, whose remission is the main goal of pha…”
BackgroundPotential Therapeutic Effects of Psilocybin: A Systematic Review
Goel, D. B., & Zilate, S. (2022) · Cureus · doi:10.7759/cureus.30214 · Cited by 50
“Despite the fact that psilocybin was the subject of the majority of clinical research recently, LSD was the exemplary hallucinogenic particle that got most of the attention in past examinations [2-3].”
BackgroundVirtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Sekula, A. D., Downey, L. A., & Puspanathan, P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.813746 · Cited by 36
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy
Mocanu, V., Mackay, L., Christie, D., & Argento, E. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00468-0 · Cited by 34
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 34
“Psycholytic therapy includes several sessions with different psychedelics, often in groups and with a varying dose range (e.g. MDMA in the first session, followed by a more intense session with LSD or a combination of both) (Passie, 1997; Reiff et al., 2020).”
BackgroundMethodInfluentialDrăgan, A.-M., Parrilla, M., Cambré, S., Domínguez‐Robles, J., Detamornrat, U., Donnelly, R. F., Oprean, R., Cristea, C., & Wael, K. D. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109257 · Cited by 29
Pogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1233743 · Cited by 36
“Several small-scale clinical studies have indicated psilocybin and LSD can alleviate depression (Bonson and Murphy, 1996; Carhart-Harris et al., 2016; Grif fi ths et al., 2016; Ross et al., 2016; Reiff et al., 2020; McClure-Begley and Roth, 2022; Goodwin et al., 2023; Holze et al., 2023).”
Williams, M. L., Korevaar, D., Harvey, R., Fitzgerald, P. B., Liknaitzky, P., O'Carroll, S., Puspanathan, P., Ross, M., Strauss, N. H. M., & Bennett–Levy, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.737738 · Cited by 31
“Reflecting the primary role of research in medical innovation, much of the recent literature on psychedelic-assisted therapies (PAT) has focused on clinical trials (4).”
BackgroundUrrutia, J., Anderson, B. T., Belouin, S. J., Berger, A. M., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., et al. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2258367 · Cited by 31
“…disorder (OCD), eating disorders, chronic pain, end-of-life or illness-related depression and anxiety, among other promising indications (Reiff et al. 2020; Andersen et al. 2021; Köck et al. 2021; Anderson et al. 2020; Ede, Bokor, and Winkelman 2016; dos; Santos et al. 2016; Rodrigues…”
BackgroundStorm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
“…or mindfulness techniques with molecules such as ketamine, psilocybin, lysergic acid diethylamide (LSD), D-Cycloserine, or neurosteroids have been proposed (Carhart-Harris et al., 2018a; Kellner et al., 2016; Pahnke et al., 1970; Schenberg, 2018; Reiff et al., 2020; Dore et al., 2019).”
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 36
“Psilocybin not only induces alterations in sensory perception (52), alleviates psychological distress (60), and augments positive emotions (55), but it is also characterized by low toxicity (61), lacks the potential for dependence or addiction (55), and generally only causes transient and…”
BackgroundProtocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 34
Wang, E. Y., Mathai, D. S., Gukasyan, N., Nayak, S. M., & Garcia‐Romeu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-78736-1 · Cited by 37
Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
McMillan, R. M. (2022) · Medical Humanities · doi:10.1136/medhum-2021-012299 · Cited by 26
“Psychedelics are regaining widespread interest as research demonstrating the potentially therapeutic applications of these compounds continues to grow (Reiff et al. 2020).”
Background(2024) · doi:10.1177/02698811231215420 · Cited by 25
“…(MDMA), have even been given Breakthrough Therapy designation from the Food and Drug Administration for the treatment of major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) respectively following promising results in phase II and III clinical trials (Reiff et al., 2020).”
BackgroundInfluentialThe Future of Enhanced Psychotherapy: Towards Precision Psychotherapy
Zipfel, S., Lutz, W., Schneider, S., Schramm, E., Delgadillo, J., & Giel, K. E. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000539022 · Cited by 31
“…effectiveness has been less prominent in recent years, but there have been interesting developments with agents with longer histories (e.g., ketamine) or use in different settings (e.g., psychedelics) [18, 28], although short-and long-term adverse effects are not yet fully understood [29].”
Felsch, C. L., & Kuypers, K. P. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104724 · Cited by 30
Qu, Y., Eguchi, A., Wan, X., Ma, L., Chang, L., Shan, J., Yang, Y. H., Mori, C., & Hashimoto, K. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.115020 · Cited by 28
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
“Data from studies show that psychedelic-assisted psychotherapy is a promising approach for the treatment of addiction (Reiff et al., 2020).”
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 31
“…Bolstridge, et al., 2016; Carhart-Harris et al., 2018, 2021; Goodwin et al., 2022; Palhano-Fontes et al., 2019; Raison et al., 2023; Reiff et al., 2020; Rotz et al., 2023; Sanches et al., 2016), anxiety with and without a life-threatening illness (Gasser et al., 2014; Griffiths et…”
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim, B., Sahin, S. S., Gee, A., Jauhar, S., Rucker, J., Salgado‐Pineda, P., Pomarol‐Clotet, E., & McKenna, P. J. (2024) · Psychological Medicine · doi:10.1017/s0033291724002496 · Cited by 32
“A 2020 review (Reiff et al., 2020) also identified four contemporary trials of psychedelics (three of psilocybin and one of LSD) for anxiety and/or depression associated with life-threatening disease, with another published since then (Holze, Gasser, Muller, Dolder, & Liechti, 2023).”
Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub
Flores-García, M., Rizzo, A., Garçon-Poca, M. Z., Fernández‐Dueñas, V., & Bonaventura, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1278023 · Cited by 29
“More recently, psychedelic drugs, which may also act through the serotonergic system but targeting serotonin receptors instead of serotonin reuptake or degradation, have been proposed as novel treatments for depression (Carhart-Harris et al., 2016; Griffiths et al., 2016; Reiff et al., 2020; Carhart-Harris et al., 202…”
BackgroundPoliti, M., Tresca, G., Menghini, L., & Ferrante, C. (2021) · Planta Medica · doi:10.1055/a-1675-3840 · Cited by 35
“Within the current trend of psychedelics renaissance and psychedelics-assisted therapy programs [133,134], a wide-ranging understanding of ethnomedicines should be therefore carefully taken into account and properly integrated; this is certainly true for ayahuasca, but probably applies to other…”
Averill, L. A., & Abdallah, C. G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2035358 · Cited by 23
“reuptake inhibitors and releasers, with impact on norepinephrine, oxytocin, prolactin), and dissociative anesthetic agents, such as ketamine (N-methyl-D-aspartate [NMDA] antagonists) [20].”
BackgroundPsychedelic Psychotherapy: Building Wholeness Through Connection
Vaid, G., & Walker, B. (2022) · Global Advances in Health and Medicine · doi:10.1177/2164957x221081113 · Cited by 26
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder
Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D., & Castle, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140009 · Cited by 30
“Although considered an entactogen and not a classic psychedelic, MDMA has some similarities in its activation of the serotonergic system and psychological effects such as feelings of empathy and connection (Reiff et al., 2020).”
BackgroundDomanegg, K., Sommer, W. H., & Meinhardt, M. W. (2023) · Cells · doi:10.3390/cells12060963 · Cited by 24
“Recent findings suggest that the use of serotonergic psychedelics in combination with psychotherapy may be a promising treatment approach for a variety of psychiatric disorders, including major depression and substance use disorders such as AUD [11,12].”
BackgroundCooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 23
Gong, P., Wang, J., Long, H., Yang, W., Chen, X., Li, N., Chen, F., Zhang, J., & Guo, Y. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70080 · Cited by 24
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 29
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
“Psychiatry is seeing a renewed interest in psychedelic compounds and their ability to treat mental health conditions (Reiff et al. 2020).”
BackgroundMoreton, S. G., Burden-Hill, A., & Menzies, R. E. (2022) · Clinical Psychologist · doi:10.1080/13284207.2022.2086793 · Cited by 20
Psychedelic Psychoanalysis: Transformations of the Self
Rundel, M. (2022) · Psychoanalytic Dialogues · doi:10.1080/10481885.2022.2106139 · Cited by 20
“Psilocybin, the active ingredient in psychedelic mushrooms, and MDMA, are in advanced stages of clinical trials, and have been granted breakthrough status by the FDA for their promise in treating PTSD, anxiety, and depression (see, Reiff et al., 2020 for a review).”
BackgroundPsychedelic discourses: A qualitative study of discussions in a Danish online forum
Holm, S., Petersen, M. A., Enghoff, O., & Hesse, M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103945 · Cited by 26
Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13127 · Cited by 26
Gonda, X., Döme, P., Serafini, G., & Pompili, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108390 · Cited by 22
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 24
“These results demonstrate the psychedelics’ potential for assisting psychotherapeutic processes (Garcia-Romeu and Richards, 2018; Reiff et al., 2020; Nayak and Johnson, 2021; Scheidegger, 2021b), rendering psychedelics a priority in psychiatric research and beyond, including pharmacological, neuroscientific, and pheno…”
Menon, V., Ramamurthy, P., Venu, S., & Andrade, C. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13778 · Cited by 28
“…PAT as the administration of study-defined psychedelic doses of classical psychedelic agents within a framework of preparatory, medication-administration, and integration sessions, while accepting between-study variations in individual components of these sessions for practical reasons [19].”
Perna, J., Trop, J., Palitsky, R., Bosshardt, Z., Vantine, H., Dunlop, B. W., & Zarrabi, A. J. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06303-z · Cited by 25
“Psilocybin is a psychedelic substance that has gained renewed public interest, including a growing body of research suggesting beneficial properties for a range of concerns for individuals experiencing mental health challenges and for healthy adults [1–4].”
McMillan, R. M., & Jordens, C. F. C. (2022) · Medicine Health Care and Philosophy · doi:10.1007/s11019-022-10070-7 · Cited by 22
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Jing, X., Hoeh, N. R., & Menkes, D. B. (2023) · Palliative & Supportive Care · doi:10.1017/s147895152300069x · Cited by 19
“1) and extends to include other hallucinogens, namely ketamine and 3,4- methylenedioxymethamphetamine (MDMA) (Reiff et al. 2020).”
BackgroundGilgoff, R., Mengelkoch, S., Elbers, J. M., Kotz, K. J., Radin, A. S., Pasumarthi, I., Murthy, R., Sindher, S., Harris, N. B., & Slavich, G. M. (2024) · Stress · doi:10.1080/10253890.2024.2327333 · Cited by 24
“…et al., 2022), positive affect treat-ment (craske et al., 2023), brain training for cognitive reap-praisal for cravings (Fisher & Berkman, 2015), neurofeedback (Greer et al., 2014), ketamine-assisted psychotherapy (Drozdz et al., 2022), and other psychedelic-assisted therapies (Reiff et al., 2020).”
BackgroundMethodInfluentialSome Comments on Psychedelic Research
Schatzberg, A. F. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030272 · Cited by 21
Do psychedelics facilitate emergence of unconscious psychological processes
Lindegaard, T. (2023) · Psychodynamic Psychiatry · doi:10.1521/pdps.2023.51.3.270 · Cited by 18
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
Villiger, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812180 · Cited by 23
Han, B., Blanco, C., Einstein, E. B., & Compton, W. M. (2022) · Addiction · doi:10.1111/add.15789 · Cited by 18
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Psychedelics and psychotherapy: is the whole greater than the sum of its parts
Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3050 · Cited by 17
Kittur, M. E., M, L. A. B., Jones, B. D. M., Blumberger, D. M., Mulsant, B. H., Rosenblat, J. D., & Husain, M. I. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119952 · Cited by 19
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 22
Brain Wellness “Spas”—Anticipating the Off-label Promotion of Psychedelics
Wexler, A., & Sisti, D. A. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1619 · Cited by 19
The Therapeutic Potential of Amphetamine-like Psychostimulants
Pires, B., Rosendo, L. M., Brinca, A. T., Simão, A. Y., Barroso, M., Rosado, T., & Gallardo, E. (2023) · Life · doi:10.3390/life13112180 · Cited by 26
“Psychedelic substances such as 3,4-methylenedioxyethylmethamphetamine (MDMA), psilocybin [5], and lysergic acid diethylamide (LSD) [6] have been studied in conjunction with therapy for various mental health conditions due to their properties [5,6].”
BackgroundSynthetic biology enables mushrooms to meet emerging sustainable challenges
Zou, G., Li, T. X., Mijakovic̀, I., & Wei, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1337398 · Cited by 20
“The FDA has designated psilocybin as a breakthrough therapeutic agent for the treatment of major depressive disorders (Reiff et al., 2020).”
Backgroundde Camargo, R. W., Joaquim, L. D. S., Machado, R. S., Ramos, S. D. S., da Rosa, L. R., Júnior, L. R. D. N., Mathias, K., Maximiano, L., Strickert, Y. R., Nord, R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04597-4 · Cited by 22
“In addition to eliciting profound psychoactive effects, AYA promotes long-lasting improvements in mental health, especially when combined with psychotherapy [14].”
Vorobyeva, N. S., & Kozlova, A. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927984 · Cited by 24
“Importantly, the current evidence verified in animal studies has shown that classical psychedelics are not associated with physical dependence, abuse or withdrawal and have a low level of toxicity (Reiff et al., 2020).”
BackgroundBerlowitz, I., Torres, E. G., Maake, C., Wolf, U., & Martin-Söelch, C. (2023) · Plants · doi:10.3390/plants12020346 · Cited by 22
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Spriggs, M. J., Murphy-Beiner, A., Murphy, R., Bornemann, J., Thurgur, H., & Schlag, A. K. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1119115 · Cited by 20
“Since 2006, there has been extensive growth, in the number of clinical trials conducted, the potential conditions for which PAT is being investigated, as well as in the number of research centers across the globe that are undertaking these trials (Aday et al., 2020; Reiff et al., 2020; Yaden et al., 2021).”
BackgroundAwake or Sleeping? Maybe Both… A Review of Sleep-Related Dissociative States
Sodré, M. E. J., Wießner, I., Irfan, M., Schenck, C. H., & Mota-Rolim, S. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123876 · Cited by 23
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Self-citationLedwos, N., Rosenblat, J. D., Blumberger, D. M., Castle, D. J., McIntyre, R. S., Mulsant, B. H., & Husain, M. I. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001608 · Cited by 20
Further education in psychedelic-assisted therapy – experiences from Switzerland
Aicher, H., Müller, F., & Gasser, P. (2025) · BMC Medical Education · doi:10.1186/s12909-025-06871-y · Cited by 20
“Currently, there is ongoing debate within the scientific and clinical community regarding the relevance and extent of psychotherapy in PAT [5, 22, 26, 32, 34, 45].”
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 17
Sicignano, D. J., Caroti, K. S., Hernández, A. V., & White, C. M. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000998 · Cited by 21
Zhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 18
What Is in a Name? The Many Meanings of “Psychedelic”
O’Donnell, K. C., Roberts, D. E., Ching, T. H. W., Glick, G., Goldway, N., Gukasyan, N., Hokansen, J., Kelmendi, B., Ross, S., Yaden, M. E., et al. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0011 · Cited by 18
Flynn, L. T., & Gao, W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02235-4 · Cited by 19
“[175]).”
Muthukumaraswamy, S. D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279736 · Cited by 20
“There is considerable scientific, public, and commercial interest in the potential for psychedelic drugs to be used medically in the treatment of a variety of disorders including, but not limited to, major depressive disorder, post-traumatic stress disorder (PTSD), and anxiety disorders [1].”
BackgroundDarke, S. G., Duflou, J. A., Peacock, A., Farrell, M., Hall, W., & Lappin, J. (2024) · Addiction · doi:10.1111/add.16518 · Cited by 17
Teaching responsible creativity: a path to ethical innovation
Rebecchi, K., Lubart, T., & Hagège, H. (2024) · Discover Education · doi:10.1007/s44217-024-00164-0 · Cited by 40
Hearn, B. (2021) · The Journal of Humanistic Counseling · doi:10.1002/johc.12164 · Cited by 20
Barnett, B. S., Ziegler, K., Doblin, R., & Carlo, A. D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221117536 · Cited by 16
“Given the recent resurgence of interest in psychedelics’ therapeutic potential (Reiff et al., 2020) and the possibility that psychedelics could return to clinical use in coming years, clarifying the relationship between psychedelic use and subsequent development of cancer has gained renewed importance.”
BackgroundThe Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge
Xu, M., Zhang, Z., Zhang, Z., Liu, D., Shang, Y., Tang, C., Wang, W., Li, H., You, B., Ying, H., et al. (2025) · Neurology International · doi:10.3390/neurolint17080120 · Cited by 20
“Psilocybin, a 5-HT 2A receptor agonist, received FDA “breakthrough therapy” designation for TRD [168].”
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 16
Geagea, D., Ogez, D., Kimble, R., & Tyack, Z. (2023) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2023.101776 · Cited by 12
Risk Factors of Suicidal Ideation in Iraqi Crystal Methamphetamine Users
Al-Imam, A., Motyka, M. A., Hoffmann, B., Al-Ka’aby, H., Younus, M. M., Al-Hemiary, N. J., & Michalak, M. (2023) · Brain Sciences · doi:10.3390/brainsci13091279 · Cited by 18
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.